1
Big Pharma Outlook 2026 Pharmavitae Analytics Report Extract
Datamonitor Healthcare Pharma intelligence I informa
Pharmavitae Analytics
Big Pharma Outlook 2026
As challenging trends in healthcare management crystallize, Big Pharma will need to tread carefully to ensure breakthroughs and innovations adequately
benefit all stakeholders across the value chain
Pfizer [1]
Sanofi [2]
GloxoSmithKline [3]
Roche [4]
AstraZeneca [5]
Novartis [6]
Merck & Co. [7]
Johnson & Johnson [8]
Eli Lilly [9]
Bristol-Myers Squibb [10]
06 07 08 09 10 11 12 13 14 15 16
[1] Pfizer
[2] Roche
[3] Merck & Co.
[4] Sanofi
[5] Johnson & John son
[6] Novartis
[7] GlaxoSmithKline
[8] AstraZeneca
[9] Bristol-Myers Squibb
[10) Eli Lilly
16 17 18 19 20 21 22 23 24 25 26
[1] Sanofi
[2] Eli Lilly
[3] AstraZeneca
[4] Merck & Co.
[5] Pfizer
[6] Johnson & Johnson
[7] Novartis
[8] GloxoSmithKline
[9] Bristol-Myers Squibb
The best coverage.The best forecasts.The best analysts.The best support.The Best of Health.
We’ve just made strategic investments in Datamonitor Healthcare to give you the best of health.
Introducing The New Datamonitor Healthcare.
We’ve quadrupled our business intelligence which covers more than 90% of prescription
medicines in the major markets. Our forecasts are tailored to your needs as events occur and
are powered by a new forecasting tool built in collaboration with a leading analytics technology provider. We’ve increased our global analyst resources by 300%, and Live Support
replies to your queries in real time, not hours, for the fastest support in the market.
Discover the best of health.
Visit: https://pharmaintelligence.informa.com/products-and-services/data-and-analysis/datamonitor-healthcare to tour the new Datamonitor Healthcare with one of our representatives.
Request a live demo and see how The Best of Health supports smarter, faster decision-making.